Switch View
© BusinessWire
13.10.2025
ISIN: US3755581036
Gilead Sciences Inc
GILD
LISTED
NASDAQ
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at the European Society for Medical Oncology (ESMO) 2025 Congress October 17 – 21.
Potentially Practice-Changing Results for First-Line Metastatic TNBC Treatment
A late-breaking presentat...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: NL0015002CX3
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast
News Preview
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date / time: Tuesday, November 4, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Wednesday, November 5, at 15:30 Frankfurt time / 14:30 London...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ISIN: US9418481035
Waters Corp
WAT
LISTED
NYSE
Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics
News Preview
Headlines:
Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1
Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between emp...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
13.10.2025
ISIN: US9418481035
Waters Corp
WAT
LISTED
NYSE
Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics
News Preview
Headlines:
Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1
Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between emp...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
13.10.2025
ISIN: US2289031005
Artivion Inc
AORT
LISTED
NYSE
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
News Preview
30-day Data from the AMDS PERSEVERE Trial Demonstrates Visceral Malperfusion Resolution in 83%, and Renal Malperfusion Resolution in 74% of Affected Subjects Post-AMDS Implantation
Real-World Data from the AMDS PROTECT Trial Validate Statistically Significant Po...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: US81663L2007
GeneDx Holdings Corp
WGS
LISTED
NASDAQ
GeneDx to Partner with Florida’s Sunshine Genetics Network, Launching Nation’s First State-Backed Genomic Newborn Screening Program
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Florida State University has selected GeneDx as one of its partners for the recently passed Sunshine Genetics Act, a groundbreaking initiative establishing the nation’s first state-backed genomic newborn screening (gNBS) program.
The S...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: US6323071042
Natera Inc
NTRA
LISTED
NASDAQ
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will host a conference call and webcast on Thursday, Oct. 23, at 5:00 a.m. PT (8:00 a.m. ET) to discuss data in muscle-invasive bladder cancer that will be presented at the European Society for Medical Oncology (ESMO) Congress. This includ...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: US74765K1051
Quantum-Si Inc
QSI
LISTED
NASDAQ
Quantum-Si to Report Third Quarter 2025 Financial Results on November 5, 2025
News Preview
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the third quarter 2025 on Wednesday, November 5, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff K...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: US36266G1076
GE Healthcare Technologies Inc
GEHC
LISTED
NASDAQ
University of Michigan study presentation at ANESTHESIOLOGY 2025 supports clinical and environmental benefits of End-tidal Control
News Preview
GE HealthCare (Nasdaq: GEHC) today announced the presentation of findings from the largest real-world evidence study to-date on End-tidal Control anesthesia delivery* software conducted at the University of Michigan. The results demonstrated the environmental and clinical benefits of End-tidal Control software and were presented at ANESTHESIOLOGY®...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ISIN: CH0499880968
ADC Therapeutics SA
ADCT
LISTED
NYSE
ADC Therapeutics Announces $60 Million Private Placement
News Preview
LAUSANNE, Switzerland, Oct. 13, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutiona...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: US1407553072
Tvardi Therapeutics Inc
TVRD
LISTED
NASDAQ
Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
News Preview
Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF)....
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ISIN: US00287Y1091
AbbVie Inc
ABBV
LISTED
EURONEXT
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
News Preview
New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-treat cancers.
NORTH CHICA...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
13.10.2025
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
News Preview
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, in rheumatoid arthritis (RA), was accepted for a late-breaking oral p...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: US69404D1081
Pacific Biosciences of California Inc
PACB
LISTED
NASDAQ
PacBio HiFi Technology Selected as Core Platform for South Korea’s National Pangenome Project
News Preview
More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ISIN: US74017N1054
Precigen Inc
PGEN
LISTED
NASDAQ
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
News Preview
15 out of 18 complete responders (83%) demonstrate continued complete response with median follow-up of 36 months
Reduction in surgeries compared to year prior to treatment with PAPZIMEOS was observed in 86% of patients in Year 1, 91%...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ISIN: BE0003739530
UCB SA
UCB
LISTED
EURONEXT
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
News Preview
First published data from a multicenter retrospective chart review study to explore the safety and efficacy of pyrimidine nucleoside and/or nucleotide therapy in patients with thymidine kinase 2 deficiency (TK2d).1
Neurology published results from a multicenter retrospective...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: US91307C1027
United Therapeutics Corp
UTHR
LISTED
NASDAQ
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting
News Preview
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced two presentations at the upcoming CHEST 2025 Annual Meeting hosted by the American College of Chest Physicians taking place October 19-22, 2025, in Chicago. In addition, United Therapeutics will sponsor and host several events including the PHinding Pulmo...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ISIN: US92556V1061
Viatris Inc
VTRS
LISTED
NASDAQ
Viatris to Participate in Upcoming Investor Conferences
News Preview
PITTSBURGH, Oct. 13, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in November 2025.
The Company will participate in a fireside chat at the UBS Global Healthcare Conference 202...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2025 to be held from October 17-21 in Berlin, Germany. Data from more than 50 company-sponsored studies, investigator-sponsored studies, and collaborations showcase result...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ISIN: US5324571083
Eli Lilly and Co
LLY
LISTED
NYSE
Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
News Preview
Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral presentation
Additional presentations showcase Lilly's robust oncology p...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
News Preview
Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases.
“IDWeek 2025 offers a cr...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: US0396971071
Ardelyx Inc
ARDX
LISTED
NASDAQ
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
News Preview
Conference call scheduled for 4:30 p.m. Eastern Time Conference call scheduled for 4:30 p.m. Eastern Time...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: NL0010872495
ProQR Therapeutics NV
PRQR
LISTED
NASDAQ
ProQR to Participate in Upcoming Investor Conferences in October 2025
News Preview
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will participate in the fo...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: US0396971071
Ardelyx Inc
ARDX
LISTED
NASDAQ
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
News Preview
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective No...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: US56400P2011
MannKind Corporation
MNKD
LISTED
NASDAQ
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
News Preview
MannKind Announces U.S. FDA Accepts for Review its sBLA for Inhaled Insulin in Children and Adolescents Aged 4-17...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: US1717571079
Cidara Therapeutics, Inc.
CDTX
LISTED
NASDAQ
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
News Preview
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will be presenting late-breaking Phase 2 clinical data on its antiviral influenza candidate, CD388, during ID Week 2025, ta...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: US19459J1043
Collegium Pharmaceutical Inc
COLL
LISTED
NASDAQ
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
News Preview
– Collegium to Ring Nasdaq Opening Bell on October 14, 2025 – – Collegium to Ring Nasdaq Opening Bell on October 14, 2025 –...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: US07725L1026
BeOne Medicines Ltd.
ONC
LISTED
NASDAQ
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, for the treatment of adult patients with relaps...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: US85916J4094
Stereotaxis Inc
STXS
LISTED
XASE
Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias
News Preview
ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced they have entered into a...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: US6979471090
Palvella Therapeutics Inc
PVLA
LISTED
NASDAQ
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations
News Preview
Second year proceeds granted following FDA review of annual performance progress report on Phase 3 SELVA single-arm, baseline-controlled trial; up to $2.6 million in non-dilutive funding anticipated over the grant period...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: CA05475P1099
AYR Wellness Inc
AYR.A
LISTED
CSE
AYR Wellness Announces Commencement of Restructuring Support Agreement Article 9 Proceedings
News Preview
MIAMI, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR”) together with its affiliates and subsidiaries (collectively, the “Company”), a leading vertically integrated U.S. multi-state cannabis operator, today announces the next step of its debt restructuring process with its senior noteholders. As contemplated...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: US0554771032
Bicara Therapeutics Inc.
BCAX
LISTED
NASDAQ
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
News Preview
Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M HNSCC Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M HNSCC...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
News Preview
REDMOND, Wash., Oct. 13, 2025 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868), a global Ph2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negativ...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: US14843C1053
Castle Biosciences Inc
CSTL
LISTED
NASDAQ
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
News Preview
Castle Biosciences will release Q3 2025 financial results and host conference call on Monday, Nov. 3, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: US5147661046
Lifecore Biomedical Inc
LFCR
LISTED
NASDAQ
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events
News Preview
CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events. Details of the company’s activities at these events are as follows:...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: US04335A1051
Arvinas, Inc.
ARVN
LISTED
NASDAQ
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
News Preview
– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial –...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: CA72706K1012
Planet 13 Holdings Inc.
PLTH
LISTED
CSE
Planet 13 Opens its Newest Florida Dispensary in DeLand just off the Busy I-4 Corridor Between Orlando and Daytona
News Preview
LAS VEGAS, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, today announced the opening of Florida dispensary in DeLand at 309 Woodland Blvd....
Themefolio
Profiler
Peergroup
© EQS Newswire
13.10.2025
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
FDA erteilt Zulassung für Lasix® ONYU* von SQ Innovation
News Preview
Gerresheimer: FDA erteilt Zulassung für Lasix® ONYU* von SQ Innovation
Innovatives Kombinationsprodukt aus Furosemid und On-Body Drug Delivery Device
Device konzipiert, entwickelt und hergestellt von Gerresheimer
Erste Produkte voraussichtlich bereits 2025 verfügbar
Düsseldorf, 13. Oktober 2025. Gerresheimer, innovativer System- und Lösungsanb......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.10.2025
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
FDA grants Approval of SQ Innovation’s Lasix® ONYU*
News Preview
Gerresheimer: FDA grants Approval of SQ Innovation’s Lasix® ONYU*
Innovative combination product of furosemide and on-body device
Device designed, developed and manufactured by Gerresheimer
First products expected to be available already in 2025
Duesseldorf, Germany, October 13, 2025. Gerresheimer, an innovative system and solution provider and......
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: AU000000IMC7
Immuron Limited
IMC
LISTED
ASX
Immuron Q1 FY26 YoY growth
News Preview
Sales Highlights (unaudited):...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH Investors Have Opportunity to Lead Molina Healthcare, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Oct. 13, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purch...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.10.2025
ISIN: CA58471K2020
Medicus Pharma Ltd.
MDCX
LISTED
TSX
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
News Preview
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel a...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ISIN: KR7006280002
Green Cross Corporation
006280
LISTED
KOE
GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine
News Preview
YONGIN, South Korea, Oct. 13, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a recombinant shingles vaccine curr...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: FR0005175080
Transgene SA
TNG
LISTED
EURONEXT
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
News Preview
Poster presentation on BT-001 in combination with pembrolizumab has shown tumor shrinkage in both injected and non-injected lesions...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
News Preview
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, held 17-21 October 2025 in Berlin, Germany. The data underscore Roche’s commitment to deliver transformative medicines for some of...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: CH0012100191
Tecan Group AG
TECN
LISTED
SIX
Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook
News Preview
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ISIN: KYG4672N1198
HUTCHMED (China) Ltd
13
LISTED
HKSE
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
News Preview
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ISIN: KYG3224E1061
Everest Medicines Limited
1952
LISTED
HKSE
Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14
News Preview
EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA).
EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is developed...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ISIN: US2300311063
Cullinan Therapeutics Inc
CGEM
LISTED
NASDAQ
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
News Preview
PRINCETON, N.J. and CAMBRIDGE, Mass., Oct. 12, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) involvement cohort of the REZILIENT2 study of zipalertinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhi...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: US6323071042
Natera Inc
NTRA
LISTED
NASDAQ
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 14 studies featuring its technology will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 17–21 in Berlin, Germany. The slate includes six oral presentations, reinforcing Natera’s position as a l...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: US03969F1093
Arcus Biosciences Inc
RCUS
LISTED
NYSE
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
News Preview
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced the first OS results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced unresectable or metastatic gastric, gastroes...
Themefolio
Profiler
Peergroup
© BusinessWire
13.10.2025
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
News Preview
Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally bioavailable KRAS G12D inhibitor, will be highlighted as oral presentations at the upcoming European Society of Medical Oncology (ESMO) Congress 20...
Themefolio
Profiler
Peergroup
© PR Newswire
12.10.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Oct. 12, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) b...
Themefolio
Profiler
Peergroup
© PR Newswire
12.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors to Inquire About Securities Class Action Investigation - MLTX
News Preview
NEW YORK, Oct. 12, 2025 /PRNewswire/ --
Why: New York, N.Y., October 12, 2025. Rosen Law Firm, a global investor rights law firm, continues to investigate potent...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.10.2025
ISIN: US60770K1079
Moderna, Inc
MRNA
LISTED
NASDAQ
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
News Preview
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in checkpoint inhibitor-resistant/refractory(...
Themefolio
Profiler
Peergroup
© PR Newswire
12.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Molina Healthcare, Inc. (MOH) - Contact Kessler Topaz Meltzer & Check, LLP
News Preview
RADNOR, Pa., Oct. 12, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Molina Healthcare, Inc. ("Molina") (NYSE: MOH) on behalf of those who purchased or otherwise acquired Molina securities...
Themefolio
Profiler
Peergroup
© BusinessWire
12.10.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
INVESTOR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) and reminds investors of the December 9, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi &...
Themefolio
Profiler
Peergroup
© PR Newswire
12.10.2025
ISIN: US28176E1082
Edwards Lifesciences Corp.
EW
LISTED
NYSE
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW
News Preview
NEW YORK, Oct. 12, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW)....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.10.2025
ISIN: US75886F1075
Regeneron Pharmaceuticals Inc
REGN
LISTED
NASDAQ
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
News Preview
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued improvement in their hearing...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
